Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers

Trial Profile

A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Middle East respiratory syndrome coronavirus vaccine - Vaccitech (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Apr 2018 Planned End Date changed from 1 Jan 2019 to 1 Mar 2019.
    • 10 Apr 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.
    • 10 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top